Lutetium Oxodotreotide not checked
Sinotau Pharmaceutical Group · 177Lu-DOTA0-Tyr3-Octreotate
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Neuroendocrine Neoplasm
- Main trialPhase 2/3
- “This is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium \[177Lu\] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced somatostatin receptor (SSTR) positive neuroendocrine neoplasms (NEN) other than grade G1/G2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and Neuroendocrine Carcinoma(NEC).”In the company’s words, NCT06398444 on ClinicalTrials.gov
- Other names
- 177Lu-DOTA0-Tyr3-Octreotate
Coming up1
- 1 Jun 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 13 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT05459844
- 13 NovCompletion date moved: 2024-06-26 to 2025-06-26 · ClinicalTrials.gov NCT05459844
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 1 Jun 2027 | A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms | |
| Phase 3Completed | 26 Jun 2025 | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026